Skip to content

Jacobson's Progressive Muscle Relaxation Technique With Aerobic Exercise on Cardiopulmonary Parameters and Quality of Life in Stage 1 Hypertensive Individuals

Additive Effects of Jacobson's Progressive Muscle Relaxation Technique With Aerobic Exercise on Cardiopulmonary Parameters and Quality of Life in Stage 1 Hypertensive Individuals

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06997445
Enrollment
40
Registered
2025-05-30
Start date
2024-08-02
Completion date
2025-06-05
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

aerobic exercise, quality of life, hypertension, Muscle Relaxation

Brief summary

The study is a randomized controlled trial. The purpose of study is to compare the additive effects of Jacobson's progressive muscle relaxation technique with aerobic exercise versus aerobic exercise on cardiopulmonary parameters including systolic and diastolic blood pressure, heart rate, respiratory rate, rate pressure product and quality of life in stage 1 hypertensive individuals.

Detailed description

The study will consist of referred stage 1 hypertensive patients by medical specialist/cardiologist. Participants will be screened through PAR-Q and IPAQ Questionnaire. Cardiac monitor will be used for assessing the cardiopulmonary parameters. SF-36 Questionnaire will be used for assessing the quality of life. Informed written consent will be taken after which participants will be recruited into two groups. Control group will be provided aerobic exercise while interventional group will be provided Jacobson's progressive muscle relaxation technique with aerobic exercise. Outcome measures assessment will be done at pre-session, at 2 weeks and after 4 weeks post-intervention

Interventions

OTHERInterventional group: Jacobson's progressive muscle relaxation technique with aerobic exercise

Jacobaon's progressive muscle relaxation technique for 15 minutes Total duration: 45 minutes

OTHERAerobic Exercise

Participants in this group will only be provided aerobic exercise for 4 weeks supervised by physiotherapist. Aerobic Exercise include the following: * Warm up exercises for 5 minutes. * Brisk walking on treadmill for 25 minutes which include warm up period for 10 minutes then 14 minutes brisk walk and cool down period included 1 minute walk. * Stepper for 5 minutes. * Static cycling for 5 minutes. * Cool down for 5 minutes. Week 03 and Week 04: Frequency: 5 days per week Intensity: 60-80% Target heart rate Time: 45 minutes Week 01 and Week 02: Frequency: 5 days per week Intensity: 50-60 % Target heart rate Time: 45 minutes

Sponsors

Foundation University Islamabad
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Adults: aged (18-45 years) * Gender: both male and female * Patients diagnosed with stage 1 hypertension (130-139 / 80-89 mmHg according to AHA/ACC 2017 guidelines * Mild to moderate physical activity level on IPAQ Questionnaire * Individuals who are able to understand and follow the instructions for exercise

Exclusion criteria

* Unstable angina, MI, heart failure, advanced CAD patients * Severe neurological, musculoskeletal, or gynaecological conditions which limit participation in study * Recent history of fracture * Morbidly obese (BMI \> 40.0 kg / m2)

Design outcomes

Primary

MeasureTime frameDescription
Systolic and diastolic blood pressure04 WeeksEvaluation will be done using cardiac monitor for blood pressure.
Heart rate04 WeeksIt will be measured through pulse oximeter.
Respiratory rate04 WeeksIt will be measured by counting the number of breaths a person takes per minute
Rate pressure product04 WeeksIt will be calculated by multiplying heart rate with systolic blood pressure

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026